Efficacy and safety of transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with cirrhosis: a meta-analysis
-
摘要:
目的比较经颈静脉肝内门体分流术(TIPS)与内镜治疗(ET)对降低肝硬化静脉曲张再出血的疗效和安全性。方法利用计算机在Pub Med、Ovid、Science Direct、Embase、万方数据库、维普数据库中检索1970年1月1日至2014年1月1日期间关于TIPS和ET预防肝硬化食管胃静脉曲张再出血疗效方面的随机对照试验,选取符合条件的随机对照试验并对其进行质量评价。使用Rev Man 5.2软件对静脉曲张再出血率、治疗后肝性脑病发生率、生存期及住院天数等指标进行Meta分析,并对其中的异质性、敏感性、偏倚作出初步判断。结果共纳入13项随机对照研究,包括TIPS组475例和ET组480例患者。结果显示,与ET相比,TIPS有着更好地控制再出血率及病死率的疗效[相对危险度(RR)=0.48,95%置信区间(CI):0.390.58,P<0.001;RR=0.37,95%CI:0.200.69,P=0.001)];但TIPS更易导致肝性脑病(RR=1.84,95%CI:1.472.30,P<0.001)。二...
-
关键词:
- 肝硬化 /
- 食管和胃静脉曲张 /
- 门体分流术,经颈静脉肝内 /
- Meta分析 /
- 治疗结果
Abstract:Objective To compare the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy (ET) in reducing recurrent variceal hemorrhage in patients with cirrhosis. Methods Data from randomized controlled trials (RCTs) ranging from January 1st, 1970 to January 1st, 2014 that compared the use of TIPS with ET for the prophylaxis of recurrent variceal bleeding in cirrhosis patients were retrieved from databases including Pub Med, Ovid, Science Direct, Embase, Wanfang Data, and CNKI. The quality of eligible RCTs was assessed, and a meta-analysis was performed on the incidence of variceal rebleeding (VRB) and post-treatment encephalopathy, deaths due to rebleeding and other causes, and hospitalization days using the Cochrane Collaboration's Rev Man 5. 2 software. Heterogeneity test and sensitivity analysis were performed, and publication biases were evaluated. Results Thirteen RCTs involving 475 cases of TIPS and480 cases of ET were recruited in our study following the inclusion criteria. The meta-analysis showed that compared with the ET group, the TIPS group had a lower incidence of VRB [relative risk (RR) = 0. 48, 95% confidence interval (CI) : 0. 39-0. 58, P < 0. 001 ], reduced deaths due to rebleeding (RR = 0. 37, 95% CI: 0. 20-0. 69, P = 0. 001) , but a higher incidence of post-treatment encephalopathy (RR = 1. 84, 95% CI: 1. 47-2. 30, P < 0. 001) . No significant differences were found in overall mortality and hospitalization days between the two groups (RR = 1. 09, 95% CI: 0. 88-1. 35, P = 0. 44; weighted mean difference =-0. 44, 95% CI:-3. 25-2. 38, P= 0. 76) . Conclusions Compared with ET, TIPS increases the risk of hepatic encephalopathy. However, in some special cases, it remains the first choice of treatment to prevent variceal rebleeding.
-
[1]HARTLING L, OSPINA M, LIANG Y, et al.Risk of bias versus quality assessment of randomised controlled trials:cross sectional study[J].BMJ, 2009, 339:b4012. [2]JADAD AR, MOORE RA, CARROLL D, et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary?[J].Control Clin Trials, 1996, 17 (1) :1-12. [3]HE HQ, CHEN K.Methods for measuring heterogeneity in a meta-analysis[J].Chin J Health Statistics, 2006, 23 (6) :486-487, 490. (in Chinese) 何寒青, 陈坤.Meta分析中的异质性检验方法[J].中国卫生统计, 2006, 23 (6) :486-487, 490. [4]CABRERA J, MAYNAR M, GRANADOS R, et al.Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage[J].Gastroenterology, 1996, 110 (3) :832-839. [5]CELLO JP, RING EJ, OLCOTT EW, et al.Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage.A randomized, controlled trial[J].Ann Intern Med, 1997, 126 (11) :858-865. [6]JALAN R, FORREST EH, STANLEY AJ, et al.A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices[J].Hepatology, 1997, 26 (5) :1115-1122. [7]RSSLE M, DEIBERT P, HAAG K, et al.Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding[J].Lancet, 1997, 349 (9058) :1043-1049. [8]SANYAL AJ, FREEDMAN AM, LUKETIC VA, et al.Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage.A randomized, controlled trial[J].Ann Intern Med, 1997, 126 (11) :849-857. [9]SAUER P, THEILMANN L, STREMMEL W, et al.Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding[J].Gastroenterology, 1997, 113 (5) :1623-1631. [10]MERLI M, SALERNO F, RIGGIO O, et al.Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis:a randomized multicenter trial.Gruppo Italiano Studio TIPS (G.I.S.T.) [J].Hepatology, 1998, 27 (1) :48-53. [11]GARCA-VILLARREAL L, MARTNEZ-LAGARES F, SIERRA A, et al.Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage[J].Hepatology, 1999, 29 (1) :27-32. [12]NARAHARA Y, KANAZAWA H, KAWAMATA H, et al.A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage[J].Hepatol Res, 2001, 21 (3) :189-198. [13]POMIER-LAYRARGUES G, VILLENEUVE JP, DESCHNES M, et al.Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis:a randomised trial[J].Gut, 2001, 48 (3) :390-396. [14]GLBERG V, SCHEPKE M, GEIGENBERGER G, et al.Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients:a randomized, controlled trial[J].Scand J Gastroenterol, 2002, 37 (3) :338-343. [15]SAUER P, HANSMANN J, RICHTER GM, et al.Endoscopic variceal ligation plus propranolol vs.transjugular intrahepatic portosystemic stent shunt:a long-term randomized trial[J].Endoscopy, 2002, 34 (9) :690-697. [16]LO GH, LIANG HL, CHEN WC, et al.A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding[J].Endoscopy, 2007, 39 (8) :679-685. [17]D'AMICO G, PAGLIARO L, BOSCH J.The treatment of portal hypertension:a meta-analytic review[J].Hepatology, 1995, 22 (1) :332-354. [18]FANELLI F, SALVATORI FM, CORONA M, et al.Stent graft in TIPS:technical and procedural aspects[J].Radiol Med, 2006, 111 (5) :709-723. [19]CHALASANI N, KAHI C, FRANCOIS F, et al.Improved patient survival after acute variceal bleeding:a multicenter, cohort study[J].Am J Gastroenterol, 2003, 98 (3) :653-659. [20]SHARARA AI, ROCKEY DC.Gastroesophageal variceal hemorrhage[J].N Engl J Med, 2001, 345 (9) :669-681. [21]YAO GB, CHEN CW, SHEN ZZ.Clinical Hepatology (2nd Edition) [M].Shanghai:Shanghai Science and Technology Press, 2011:694-699. (in Chinese) 姚光弼, 陈成伟, 沈稚舟.临床肝脏病学 (第二版) [M].上海:上海科学技术出版社, 2011:694-699. [22]QUAN QZ, QI F, WANG YJ, et al.Evaluation of endoscopic ligation and sclerosing agent in treatment of esophageal varices[J].Chin J Dig Endosc, 1997, 14 (5) :311-312. (in Chinese) 权启镇, 齐风, 王要军, 等.内镜下食管静脉曲张结扎加硬化剂疗法的评价[J].中华消化内镜杂志, 1997, 14 (5) :311-312. [23]WU LM, WU JM, LIU Y, et al.Analysis of risk factors for early rebleeding in cirrhotic patients with esophageal variceal bleeding[J].The J Pract Med, 2009, 25 (22) :3803-3805. (in Chinese) 吴利敏, 吴金明, 刘扬, 等.肝硬化食管静脉曲张破裂出血早期再出血的危险因素分析[J].实用医学杂志, 2009, 25 (22) :3803-3805. [24]YANG X, ZOU DJ, LIANG HL.Prediction of re-bleeding and death risk in patients with esophageal varices by MELD model combined with endoscopy[J].Med J Natl Defending Forces Southwest China, 2012, 22 (1) :27-29. (in Chinese) 杨曦, 邹代军, 梁红亮.MELD结合内镜预测食管静脉曲张再出血和死亡风险的研究[J].西南国防医药, 2012, 22 (1) :27-29. [25]ALBILLOS A, TEJEDOR M.Secondary prophylaxis for esophageal variceal bleeding[J].Clin Liver Dis, 2014, 18 (2) :359-370.
计量
- 文章访问数: 2826
- HTML全文浏览量: 16
- PDF下载量: 611
- 被引次数: 0